Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Accounts Payable
Mayne Pharma Group Ltd
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Accounts Payable
AU$32m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Accounts Payable
AU$1.7m
|
CAGR 3-Years
41%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accounts Payable
AU$3.4m
|
CAGR 3-Years
66%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Accounts Payable
AU$1.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
|
Probiotec Ltd
ASX:PBP
|
Accounts Payable
AU$30.7m
|
CAGR 3-Years
41%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accounts Payable
AU$2.8m
|
CAGR 3-Years
163%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Accounts Payable?
Accounts Payable
32m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Accounts Payable amounts to 32m AUD.
What is Mayne Pharma Group Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-13%
Over the last year, the Accounts Payable growth was -50%. The average annual Accounts Payable growth rates for Mayne Pharma Group Ltd have been 2% over the past three years , -13% over the past five years .